Molecular and clinical effects of notch inhibition in glioma patients: A phase 0/I trial

Clinical Cancer Research

Volumn 22, Issue 19, 2016, Pages 4786-4796

  Xu, Ran ^a,b   Shimizu, Fumiko ^a   Hovinga, Koos ^a   Beal, Kathryn ^a   Karimi, Sasan ^a   Droms, Leif ^a   Peck, Kyung K ^a   Gutin, Philip ^a   Iorgulescu, J Bryan ^a,g   Kaley, Thomas ^a   DeAngelis, Lisa ^a   Pentsova, Elena ^a   Nolan, Craig ^a   Grommes, Christian ^a   Chan, Timothy ^a   Bobrow, Dylan ^a   Hormigo, Adilia ^a,c   Cross, Justin R ^a   Wu, Nian ^a,d   Takebe, Naoko ^e   Panageas, Katherine ^a   Ivy, Percy ^e   Supko, Jeffrey G ^f   Tabar, Viviane ^a   Omuro, Antonio ^a   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d LipoSeuticals Inc   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; CD133 ANTIGEN; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; NOTCH RECEPTOR; TEMOZOLOMIDE; 2,2-DIMETHYL-N-(6-OXO-6,7-DIHYDRO-5H-DIBENZO(B,D)AZEPIN-7-YL)-N'-(2,2,3,3,3-PENTAFLUOROPROPYL)MALONAMIDE; BENZAZEPINE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN SURGERY; CANCER CELL; CANCER INHIBITION; CANCER INITIATING CELL; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG PENETRATION; DRUG TOLERABILITY; DRUG TUMOR LEVEL; ELECTROLYTE DISTURBANCE; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; GLIOBLASTOMA; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PLASMA VOLUME; PRIORITY JOURNAL; PROTEIN DOMAIN; QT PROLONGATION; SIDE EFFECT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; UPREGULATION; ANTAGONISTS AND INHIBITORS; BRAIN TUMOR; CANCER STEM CELL; CHEMORADIOTHERAPY; CLINICAL TRIAL; DRUG EFFECTS; GLIOMA; MAXIMUM TOLERATED DOSE; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROCEDURES; TUMOR RECURRENCE;

ADULT; AGED; BENZAZEPINES; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; FEMALE; GLIOMA; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, NOTCH;

EID: 84991211970     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-0048     Document Type: Article

References (36)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
2. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014;370:699-708.
3. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014;370:709-22.
4. Singh SK, Clarke ID, Hide T, Dirks PB. Cancer stem cells in nervous system tumors. Oncogene 2004;23:7267-73.
5. Louvi A, Artavanis-Tsakonas S. Notch signalling in vertebrate neural development. Nat Rev Neurosci 2006;7:93-102.
6. Purow BW, Haque RM, Noel MW, Su Q, BurdickMJ, Lee J, et al. Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res 2005;65:2353-63.
7. Benedito R, Roca C, Sorensen I, Adams S, Gossler A, Fruttiger M, et al. The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell 2009;137:1124-35.
8. Abravanel DL, Belka GK, Pan TC, Pant DK, Collins MA, Sterner CJ, et al. Notch promotes recurrence of dormant tumor cells following HER2/neutargeted therapy. J Clin Invest 2015;125:2484-96.
9. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009;137:216-33.
10. Gordon WR, Vardar-Ulu D, Histen G, Sanchez-Irizarry C, Aster JC, Blacklow SC. Structural basis for autoinhibition of Notch. Nat Struct Mol Biol 2007;14:295-300.
11. Hovinga KE, Shimizu F, Wang R, Panagiotakos G, Van Der Heijden M, Moayedpardazi H, et al. Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cells 2010;28:1019-29.
12. Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, White RR, et al. Notch promotes radioresistance of glioma stem cells. Stem Cells 2010;28: 17-28.
13. Saito N, Fu J, Zheng S, Yao J, Wang S, Liu DD, et al. A high Notch pathway activation predicts response to gamma secretase inhibitors in proneural subtype of glioma tumor-initiating cells. Stem Cells 2014;32:301-12.
14. Fan X, Khaki L, Zhu TS, Soules ME, Talsma CE, Gul N, et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 2010;28:5-16.
15. Dantas-Barbosa C, Bergthold G, Daudigeos-Dubus E, Blockus H, Boylan JF, Ferreira C, et al. Inhibition of the NOTCH pathway using gamma-secretase inhibitor RO4929097 has limited antitumor activity in established glial tumors. Anti-Cancer Drug 2015;26:272-83.
16. Purow B. Notch inhibition as a promising new approach to cancer therapy. Adv Exp Med Biol 2012;727:305-19.
17. Olsauskas-Kuprys R, Zlobin A, Osipo C. Gamma secretase inhibitors of Notch signaling. Onco Targets Ther 2013;6:943-55.
18. Luistro L, He W, Smith M, Packman K, Vilenchik M, Carvajal D, et al. Preclinical profile of a potent gamma-secretase inhibitor targeting notch signalingwith in vivo efficacy and pharmacodynamic properties. Cancer Res 2009;69:7672-80.
19. Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, et al. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol 2012;30:2348-53.
20. LoConte NK, Razak AR, Ivy P, Tevaarwerk A, Leverence R, Kolesar J, et al. A multicenter phase 1 study of gamma-secretase inhibitor RO4929097 in combinationwith capecitabine in refractory solid tumors. InvestNewDrug 2015;33:169-76.
21. Diaz-Padilla I, Hirte H, Oza AM, Clarke BA, Cohen B, Reedjik M, et al. A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. Invest NewDrug 2013;31:1182-91.
22. Strosberg JR, Yeatman T, Weber J, Coppola D, Schell MJ, Han G, et al. A phase II study of RO4929097 in metastatic colorectal cancer. Eur J Cancer 2012;48:997-1003.
23. Sahebjam S, Bedard PL, Castonguay V, Chen Z, Reedijk M, Liu G, et al. A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503). Brit JCancer 2013;109: 943-9.
24. Richter S, Bedard PL, Chen EX, Clarke BA, Tran B, Hotte SJ, et al. A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). Invest New Drug 2014;32:243-9.
25. Krop I, Demuth T, Guthrie T, Wen PY, Mason WP, Chinnaiyan P, et al. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol 2012;30:2307-13.
26. Li JL, Sainson RC, ShiW, Leek R, Harrington LS, PreusserM, et al. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res 2007;67:11244-53.
27. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, GaleNW, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006;444:1032-7.
28. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006;444:1083-7.
29. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature 2004;432: 396-401.
30. Stockhausen MT, Kristoffersen K, Poulsen HS. The functional role of Notch signaling in human gliomas. Neuro-oncology 2010;12:199-211.
31. Zhu TS, Costello MA, Talsma CE, Flack CG, Crowley JG, Hamm LL, et al. Endothelial cells create a stem cell niche in glioblastoma by providing NOTCH ligands that nurture self-renewal of cancer stem-like cells. Cancer Res 2011;71:6061-72.
32. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 2010;463:318-25.
33. Pitz MW, Desai A, Grossman SA, Blakeley JO. Tissue concentration of systemically administered antineoplastic agents in human brain tumors. J Neuro Oncol 2011;104:629-38.
34. Pourquie O. Vertebrate segmentation: from cyclic gene networks to scoliosis. Cell 2011;145:650-63.
35. Woltje K, JabsM, Fischer A. Serum induces transcription of hey1 and hey2 genes by alk1 but not notch signaling in endothelial cells. PLoS One 2015;10:e0120547.
36. Takebe N, Nguyen D, Yang SX. Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther 2014;141: 140-9.